SILO PHARMA INC

Company Overview

Silo Pharma Inc. is a development-stage biotechnology company focusing on CNS and rare-disease therapeutics, including both conventional drugs and psychedelic formulations. Its lead programs include SPC-15 (intranasal 5‑HT4 agonist for PTSD/anxiety, IND-enabling work and GLP toxicology dosing underway), SP-26 (time‑release ketamine implant for fibromyalgia in preclinical stages), SPC-14 (Alzheimer’s candidate) and SPU-16 (CNS‑homing peptide for targeted liposomal delivery). The company follows an asset‑light model centered on university licensing, sponsored research and external development partnerships (Columbia, UMB, UCSF), carries modest near‑term revenues from license recognition, and reported accelerating R&D spend and operating losses as it advances IND-enabling work. With only a few full‑time employees and concentrated vendor/license relationships, Silo is highly dependent on milestone progress, regulatory milestones (FDA/DEA), and further financing to execute its strategy.

Executive Compensation Practices

Given the company’s small headcount, development-stage profile and cash constraints, executive pay is likely skewed toward equity and stock‑based compensation rather than high cash salaries—consistent with the reported modest cash compensation ($906k aggregate) and rising stock‑based pay. Performance drivers that should anchor incentive design include IND submission/completion milestones (e.g., SPC‑15 IND), patent and licensing milestones, sponsored‑research progress, fundraising success, and out‑licensing or partnership deals; R&D progress (R&D expense rose 180% to $2.37M) will be a primary measurable metric. Expect use of time‑vested and milestone‑contingent equity grants, and possibly option or warrant-heavy packages to preserve cash while aligning management with long‑term value creation; disclosures around dilution and derivative instruments (warrants) are important. Regulatory and DEA/CSA controls on psychedelic/ketamine products and the company’s recent non‑traditional treasury moves (August 2025 crypto strategy) create additional governance and disclosure factors that compensation committees may consider when setting clawbacks, hold periods, or performance conditions.

Insider Trading Considerations

Because Silo is small, thinly traded and milestone‑driven, insider buys or sells can be highly informative and price‑moving; material events to watch are IND filings/acceptance, GLP tox completions, licensing milestones and sponsored‑research milestones. Trading by insiders may reflect liquidity needs (e.g., warrant exercises or equity financings that have historically funded operations) rather than negative signals, so patterns tied to financing rounds or treasury management (including the new crypto strategy) should be interpreted in context. Regulatory sensitivity around psychedelic/ketamine approvals increases the likelihood of market‑moving confidential information, so expect insider blackout periods, 10b5‑1 plans or careful disclosure timing around such events; any insider transactions near DEA/FDA announcements or licensing milestone payments warrant extra scrutiny. Finally, concentrated ownership and related‑party license relationships (Columbia/UMB representing material vendor/license exposure) mean insider trades may also correlate with non‑operational corporate actions (license fees, sponsored‑research closes), not solely clinical progress.